Compare TotalEnergies SE (TTE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TotalEnergies SE vs State Street SPDR S&P Biotech ETF — how do they compare? TotalEnergies SE trades at $87.47 (market cap $196.06B), while State Street SPDR S&P Biotech ETF trades at $159.76. The key difference: TotalEnergies SE pays a 4.82% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, TotalEnergies SE nearer its low. Which is the better fit depends on your goals.
| TTE | XBI | |
|---|---|---|
Market Cap | $196.06B | — |
Sector | Energy | Broad Market / Factor |
52-Week High | $93.60 | $164.28 |
52-Week Low | $57.39 | $86.92 |
Enterprise Value | $227.06B | — |
Dividend Yield | 4.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TotalEnergies SE (TTE) trades at $87.96, up 2.48% today, with a bullish technical signal and strong analyst support. Recent earnings show mixed quarterly beats, while the company expands in renewables and gas projects. Valuation ratios like P/E of 11.01 and P/S of 0.98 appear attractive relative to sector peers.
The outlook is positive given strategic acquisitions and gas field developments, but risks include revenue declines and legal challenges. With a consensus price target of $94.00 and 57.58% buy ratings, the stock offers upside potential amid energy transition opportunities.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
